SCHEMBL6285277

SCHEMBL6285277

COc1ccc(COC(=O)C(=O)OCc2ccc(Cl)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.56
POLB P06746 3/20 0.53
LMNA P02545 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
ALDH1A1 P00352 3/20 0.53
CNR2 P34972 1/20 0.52
MAOA P21397 1/20 0.51
MAOB P27338 1/20 0.51
KLK7 P49862 1/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
CNR1 P21554 1/20 0.50
FPR2 P25090 1/20 0.50
HTT P42858 1/20 0.50
EGFR P00533 1/20 0.50
ERBB2 P04626 1/20 0.50
GAA P10253 2/20 0.49
KDM4E B2RXH2 1/20 0.49
MAPT P10636 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3758807 0.91 ALDH1A1 (0.60) POLBSMN1; SMN2ALDH1A1HTTMAPT
SCHEMBL28142 0.87 IDO1 (0.52) POLBALDH1A1MAOAMAOBMEN1
SCHEMBL28711475 0.86 ALDH1A1 (0.59) POLBSMN1; SMN2ALDH1A1KMT2AHTT
SCHEMBL1521953 0.84 LTA4H (0.58) POLBSMN1; SMN2ALDH1A1HTTMAPT
SCHEMBL8645685 0.84 ALDH1A1 (0.54) HPGDPOLBSMN1; SMN2ALDH1A1MAOB
SCHEMBL6158485 0.83 ALDH1A1 (0.62) HPGDPOLBLMNASMN1; SMN2ALDH1A1
SCHEMBL8641118 0.82 NPC1 (0.56) POLBSMN1; SMN2ALDH1A1HTT
Carbamic Acid SCHEMBL30096670 0.81 KMT2A (0.58) HPGDPOLBSMN1; SMN2ALDH1A1MAOA
SCHEMBL722902 0.80 ALDH1A1 (0.60) POLBSMN1; SMN2ALDH1A1HTTMAPT
SCHEMBL11109286 0.80 ALDH1A1 (0.50) POLBSMN1; SMN2ALDH1A1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6933288-B2 Pyranosyl cytosines: pharmaceutical formulations and methods ISIS PHARMACEUTICALS, INC. 2005-08-23 US disclosed
US-20030216575-A1 Novel pyranosyl cytosines: pharmaceutical formulations and methods ISIS PHARMACEUTICALS, INC. 2003-11-20 US disclosed
WO-2003066633-A1 NOVEL PYRANOSYL CYTOSINES: PHARMACEUTICAL FORMULATIONS AND METHODS ISIS PHARMACEUTICALS, INC. (US) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216575-A1 Novel pyranosyl cytosines: pharmaceutical formulations and methods RNGTT, NOP2, RNMT HPGD 4079/4885POLB 344/4885LMNA 3539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.